Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis
Background and Aims. Portal vein thrombosis is a serious adverse event that occurs during liver cirrhosis. We performed a meta-analysis to evaluate the safety and efficacy of anticoagulant therapy and prophylactic anticoagulant therapy in cirrhosis patients with (/without) portal vein thrombosis. Me...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2021/8859602 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554595344187392 |
|---|---|
| author | Huan Chen Jiaming Lei Sicheng Liang Gang Luo Mingming Deng Muhan Lü |
| author_facet | Huan Chen Jiaming Lei Sicheng Liang Gang Luo Mingming Deng Muhan Lü |
| author_sort | Huan Chen |
| collection | DOAJ |
| description | Background and Aims. Portal vein thrombosis is a serious adverse event that occurs during liver cirrhosis. We performed a meta-analysis to evaluate the safety and efficacy of anticoagulant therapy and prophylactic anticoagulant therapy in cirrhosis patients with (/without) portal vein thrombosis. Methods. Eligible comparative studies were identified by searching the following electronic databases: PubMed, Embase, Cochrane Library, Web of Science, and CNKI. A meta-analysis was performed to calculate odds ratios and 95% confidence intervals using fixed-effects models. Recanalization and thrombus progression were defined as the primary outcomes. Secondary outcomes included adverse events and death mortality. Results. A total of 3479 patients were included in this analysis. Compared with the control group, the recanalization rate in the anticoagulant therapy group was increased P<0.00001 in patients with cirrhosis and portal vein thrombosis without increasing adverse events. Multiple use of enoxaparin in small doses is safer than single large doses P=0.004. Direct oral anticoagulants are more effective P<0.00001 and safer than traditional anticoagulants. Prophylactic anticoagulant therapy can effectively prevent portal vein thrombosis formation P<0.00001. Conclusions. Anticoagulation therapy can treat or prevent portal vein thrombosis in patients with liver cirrhosis and is a relatively safe treatment. |
| format | Article |
| id | doaj-art-ca6b333d7d0f4108ad218391a74e930d |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-ca6b333d7d0f4108ad218391a74e930d2025-02-03T05:51:11ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972021-01-01202110.1155/2021/88596028859602Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-AnalysisHuan Chen0Jiaming Lei1Sicheng Liang2Gang Luo3Mingming Deng4Muhan Lü5Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, ChinaBackground and Aims. Portal vein thrombosis is a serious adverse event that occurs during liver cirrhosis. We performed a meta-analysis to evaluate the safety and efficacy of anticoagulant therapy and prophylactic anticoagulant therapy in cirrhosis patients with (/without) portal vein thrombosis. Methods. Eligible comparative studies were identified by searching the following electronic databases: PubMed, Embase, Cochrane Library, Web of Science, and CNKI. A meta-analysis was performed to calculate odds ratios and 95% confidence intervals using fixed-effects models. Recanalization and thrombus progression were defined as the primary outcomes. Secondary outcomes included adverse events and death mortality. Results. A total of 3479 patients were included in this analysis. Compared with the control group, the recanalization rate in the anticoagulant therapy group was increased P<0.00001 in patients with cirrhosis and portal vein thrombosis without increasing adverse events. Multiple use of enoxaparin in small doses is safer than single large doses P=0.004. Direct oral anticoagulants are more effective P<0.00001 and safer than traditional anticoagulants. Prophylactic anticoagulant therapy can effectively prevent portal vein thrombosis formation P<0.00001. Conclusions. Anticoagulation therapy can treat or prevent portal vein thrombosis in patients with liver cirrhosis and is a relatively safe treatment.http://dx.doi.org/10.1155/2021/8859602 |
| spellingShingle | Huan Chen Jiaming Lei Sicheng Liang Gang Luo Mingming Deng Muhan Lü Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis Canadian Journal of Gastroenterology and Hepatology |
| title | Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis |
| title_full | Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis |
| title_fullStr | Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis |
| title_full_unstemmed | Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis |
| title_short | Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis |
| title_sort | safety and efficacy of anticoagulation in patients with cirrhosis a meta analysis |
| url | http://dx.doi.org/10.1155/2021/8859602 |
| work_keys_str_mv | AT huanchen safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis AT jiaminglei safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis AT sichengliang safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis AT gangluo safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis AT mingmingdeng safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis AT muhanlu safetyandefficacyofanticoagulationinpatientswithcirrhosisametaanalysis |